Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
<blockquote class="twitter-tweet" lang="en"><p><a href="https://twitter.com/jimcramer">@jimcramer</a> Lakewood resorts & breaks law by employing underage paid bashers on opk message/Yahoo boards <a href="http://t.co/qcgOWcfr9I">pic.twitter.com/qcgOWcfr9I</a></p>— curtis sandy (@recognizer007) <a href="https://twitter.com/recognizer007/statuses/448640250143707136">March 26, 2014</a></blockquote>
<script async src="//platform.twitter.com/widgets.js" charset="utf-8"></script>
Thanks,why did NITE take it down? Loading for run?46 Million could pop FTWR huge with news.
What is the AS OS & Float???
OPKO Health, INC
American Urological Association (AUA) Accepts 4Kscore Test Clinical Study for Plenary Presentation at 2014 Annual Meeting
MIAMI--(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK) today announced that the American Urological Association (AUA) has accepted "The 4KscoreTM Test as a Predictor of High-Grade Prostate Cancer on Biopsy" as a Late-Breaking Abstract for presentation in Plenary I on Sunday May 18, 2014 at the AUA Annual meeting in Orlando, FL.
The data accepted are from a prospective, blinded study conducted at 26 urology clinics across the United States from October 2013 to January 2014. The data confirm the accuracy of the 4KscoreTMalgorithm in a United States population of men referred for prostate biopsy. The 4KscoreTM algorithm, which is based on the values of four different kallikrein blood tests (total PSA, free PSA, intact PSA and hK2) plus age, DRE and prior biopsy status, was originally studied in multiple European cohorts involving over 10,000 patients.
"These are challenging times in urology as we are seeing a decline in men screened for prostate cancer with PSA, yet we know that mortality from prostate cancer has steadily declined since the introduction of PSA screening," said Dr. Stephen M. Zappala, MD FACS of Andover Urology. "The 4KscoreTM test offers new information on the probability of having a Gleason Score = 7 cancer prior to undergoing a prostate biopsy. This is important, because we know that besides the potential side effects of biopsy such as bleeding and infection, up to 80% of prostate biopsies will either be negative for prostate cancer or will indicate a low grade disease that may be better monitored than treated. The 4KscoreTM test will offer both the Urologist and patient new information for the shared decision-making discussion about whether or not to have a prostate biopsy."
"Acceptance as a late-breaking abstract highlights both the quality of the clinical data for the 4KscoreTM test and the urgent need to have a solution for more effective biomarker-based tests for managing prostate cancer risk and the disease itself," said David Okrongly, President of OPKO Diagnostics. "We are looking forward to presenting the full US clinical trial data at the AUA meeting in May."
"The results of the US clinical study are now complete and we are pleased to also announce that we are on track for launch of the 4Kscore Test on March 31, 2014," said Phillip Frost, M.D., OPKO's Chairman and Chief Executive Officer.
About the 4Kscore™ Test
The 4Kscore™ is a convenient blood test that measures the serum levels of four different prostate-derived kallikrein proteins: total PSA, free PSA, intact PSA and hK2. Levels of these biomarkers are combined with a patient's age and digital rectal exam (DRE) status using a proprietary algorithm to calculate the probability of a finding of aggressive prostate cancer. The 4Kscore™ test is based on over a decade of research of the four kallikrein panel of biomarkers conducted by scientists at Memorial Sloan Kettering Cancer Center and leading research centers in Europe on over 10,000 patients. The information provided by the 4Kscore™ test can help facilitate the shared decision-making process between urologist and patient in determining the advisability of a prostate biopsy.
About Prostate Cancer
In 2013, over 238,000 new cases of prostate cancer will be identified and 29,720 men will die from the disease, according to estimates released by the National Cancer Institute, making it the second most deadly cancer in U.S. men. Prostate cancer is usually first detected by elevations in serum PSA. However, PSA level is often high for reasons unrelated to prostate cancer and, since an elevated PSA level often leads to biopsy, 75% of all prostate biopsies performed are either negative or indicate a low likelihood of aggressive cancer.
ABOUT OPKO HEALTH, INC.
OPKO is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development and commercialization expertise and novel and proprietary technologies. For more information, visit http://www.opko.com.
OPK possible be in elliott wave 5 after break of 11.60ish.
1295 1
9.36 2
11.60 3
7.32 4
5 ??????????????????? Draw a trendline
Who cares about retail,I'm going with big boyz and what all that spectrum will be worth.
Oppenheimer bullish on OPKO “Investors underestimate” Upside
Pharma company of Philip Frost gets warm recommendation today from Oppenheimer’s Research Department, began to cover on recommendation of ‘Outperform’
Research Department at Oppenheimer started today covering the stock Opko Health.
A recommendation of ‘Outperform’ with a target price of $ 13, meaning upside of nearly 40% over yesterday’s closing price.
Analysts explain the target price sums up all parts “because the company has a wide range of products.”
Looking ahead, Oppenheimer marks a number of key products.
Opko Health is expected to launch two diagnostics products in 2015, and two pharma products in 2016, which we believe to be the most significant valuation,” write the research department.
They point out that the main focus should be on the diagnostic products, especially 4Kscore and Claros-1, although Opko is known more for its drug pipeline.
Overall perspective, Oppenheimer assessment is that investors underestimate their assessment of the potential of 4Kscore, and they expect that the product will expand well beyond the target market it is targeting.
The 4Kscore intended to diagnose prostate cancer, is expected to market to about a million customers, and will also in the long term a much broader market of about 30 million customers, according to Oppenheimer.
Analysts estimate that the 4Kscore has a value of about $ 5 per share.
Other products that add value are Claros-1 (a value of $ 2.5 per share), Rayaldy in a Phase 3 clinical trial right now (about $ 4 per share) and hGH-CTP ($ 1.5) per share.
Now give a PE and throw in SQUEEEZ and $30?????????????????????????????????????
Oppenheimer bullish on OPKO “Investors underestimate” Upside
Pharma company of Philip Frost gets warm recommendation today from Oppenheimer’s Research Department, began to cover on recommendation of ‘Outperform’
Research Department at Oppenheimer started today covering the stock Opko Health.
A recommendation of ‘Outperform’ with a target price of $ 13, meaning upside of nearly 40% over yesterday’s closing price.
Analysts explain the target price sums up all parts “because the company has a wide range of products.”
Looking ahead, Oppenheimer marks a number of key products.
Opko Health is expected to launch two diagnostics products in 2015, and two pharma products in 2016, which we believe to be the most significant valuation,” write the research department.
They point out that the main focus should be on the diagnostic products, especially 4Kscore and Claros-1, although Opko is known more for its drug pipeline.
Overall perspective, Oppenheimer assessment is that investors underestimate their assessment of the potential of 4Kscore, and they expect that the product will expand well beyond the target market it is targeting.
The 4Kscore intended to diagnose prostate cancer, is expected to market to about a million customers, and will also in the long term a much broader market of about 30 million customers, according to Oppenheimer.
Analysts estimate that the 4Kscore has a value of about $ 5 per share.
Other products that add value are Claros-1 (a value of $ 2.5 per share), Rayaldy in a Phase 3 clinical trial right now (about $ 4 per share) and hGH-CTP ($ 1.5) per share.
Now give a PE and throw in SQUEEEZ and $30?????????????????????????????????????
Oppenheimer bullish on OPKO “Investors underestimate” Upside
Pharma company of Philip Frost gets warm recommendation today from Oppenheimer’s Research Department, began to cover on recommendation of ‘Outperform’
Research Department at Oppenheimer started today covering the stock Opko Health.
A recommendation of ‘Outperform’ with a target price of $ 13, meaning upside of nearly 40% over yesterday’s closing price.
Analysts explain the target price sums up all parts “because the company has a wide range of products.”
Looking ahead, Oppenheimer marks a number of key products.
Opko Health is expected to launch two diagnostics products in 2015, and two pharma products in 2016, which we believe to be the most significant valuation,” write the research department.
They point out that the main focus should be on the diagnostic products, especially 4Kscore and Claros-1, although Opko is known more for its drug pipeline.
Overall perspective, Oppenheimer assessment is that investors underestimate their assessment of the potential of 4Kscore, and they expect that the product will expand well beyond the target market it is targeting.
The 4Kscore intended to diagnose prostate cancer, is expected to market to about a million customers, and will also in the long term a much broader market of about 30 million customers, according to Oppenheimer.
Analysts estimate that the 4Kscore has a value of about $ 5 per share.
Other products that add value are Claros-1 (a value of $ 2.5 per share), Rayaldy in a Phase 3 clinical trial right now (about $ 4 per share) and hGH-CTP ($ 1.5) per share.
Now give a PE and throw in SQUEEEZ and $30?????????????????????????????????????
Very nice and more upgrades to come...hold on tight..we have a huge winner with a squeez.
Cup & Handle pattern @ $12.00ish,measured move from there is $17
Somethings up with accumulation.
Here's what sorros is doing.
Opko Health Inc. (OPK): CEO & Chairman, 10% Owner Phillip Frost Md Et Al Bought 56,500 Shares
CEO and Chairman, 10% Owner of Opko Health Inc. (OPK) Phillip Frost Md Et Al bought 56,500 shares during the past week at an average price of $9.19. Opko Health Inc. was originally incorporated in Delaware in October 1991 under the name Cytoclonal Pharmaceutics Inc. Opko Health Inc. has a market cap of $3.79 billion; its shares were traded at around $9.19 with and P/S ratio of 31.69.
Opko recently reported its fourth quarter and full year 2013 financial results. For the fourth quarter of 2013, consolidated revenues increased about 30% to $20.7 million from $16.2 million in the prior year period. For the year ended Dec. 31, 2013, consolidated revenues more than doubled to $96.5 million from $47.0 million in the prior year.
George Soros (Trades, Portfolio) owns 844,600 shares as of 12/31/2013, an increase of 13.37% from the previous quarter. This position accounts for 0.061% of the $11.78 billion portfolio of Soros Fund Management LLC. Mario Gabelli (Trades, Portfolio) owns 15,000 shares as of 12/31/2013, which accounts for 0.0007% of the $18.65 billion portfolio of GAMCO Investors.
Vice Chairman and CTO Jane Hsiao Ph.D. bought 10,000 shares of OPK stock on 01/30/2014 at the average price of $8.14. Jane Hsiao Ph.D. owns at least 36,818,758 shares after this. The price of the stock has increased by 12.9% since.
Sony DADC and OPKO Diagnostics Announce Manufacturing Partnership
Mar 10, 2014 11:38:00 (ET)
Sony DADC and OPKO Diagnostics enter into a supply agreement for high-volume manufacturing of components for the OPKO Sangia(TM) microfluidic test cassette
SALZBURG, Austria & MIAMI--(BUSINESS WIRE)--March 10, 2014--
OPKO Diagnostics, a division of OPKO Health, Inc. (NYSE:OPK), and Sony DADC today announced the signing of a supply agreement for high volume production of a key component of the OPKO Sangia(TM) microfluidic cassette. The Sangia cassettes are designed to perform quantitative immunoassays from a finger-stick blood sample on the Claros(R)1 in-office analyzer. The test results are reported in the physician's office in 10 minutes. The first two OPKO Sangia tests are for total prostate specific antigen (Total PSA) and Total Testosterone.
Sony DADC BioSciences, the leading OEM supplier of smart polymer-based consumables, is using their ISO 13485 facility in Salzburg, Austria, to manufacture to OPKO Diagnostics' specifications.
"We are pleased to be partnered with Sony DADC, a world leader in high precision consumable manufacturing, for production of Sangia technology components," said David Okrongly, president of OPKO Diagnostics. "It is critical to us that Sony DADC also meets the regulatory demands of our in vitro diagnostic products and is manufacturing to the ISO 13485 quality standard."
"We are delighted to have gained the trust of the team at OPKO Diagnostics. Based on our extensive experience in translating polymer science into robust manufacturing processes, we look forward to supplying the Sangia microfluidic components to OPKO Diagnostics as they grow their global business footprint," said Dr. Chris Mauracher, Senior Vice President of the BioSciences division of Sony DADC.
About Sony DADC
Building on Sony DADC's experience in high-precision optical disk manufacturing, Sony DADC's BioSciences division partners with Life Sciences and Diagnostics companies enabling the industrial manufacturing of smart polymer parts. Sony DADC's global set-up comprises production sites, distribution hubs, digital & service facilities in 19 countries worldwide, including Japan, the US and Europe. For more information please visit: http://biosciences.sonydadc.com/home/.
It was taken from the yahedge messege board and if you look @ the first 3 words..."I suspect." is far from FACTS.
John Dooley is deeply involved with GSAT and is also deeply involved with Fibertower.
Rest assured that any possible synergies are being well explored with Jay Monroe.
The debt holders are entitled to settlement at face plus costs, but someone will get a windfall.
Of course the debt holders want to accelerate foreclosure to reap the windfall.
It appears there is doubt on the FCCs move. If the FCC takes back the licenses, then they can be re-auctioned with the proceeds going to the Federal coffers.
If the FCC does not snap back the licenses, if the debt holders cannot complete their seizure of assets through the courts in time, IFFFF the judge is honest, and if someone wants to come forth with the cash and / or stock to buy everyone involved in the bankruptcy out, the it could work.
I would give it a 50-50 chance of Dooley / Monroe pulling this off. Monroe has much on his plate getting GSAT's TLPS rolling.
The time it takes to put together such a deal is geometrically proportionate to the number of parties involved.
Let the crisis develop, then step in at the last minute appears to be the only strategy that could work with the debt holders and the courts, but the FCC is involved.
Of course Monroe & Dooley are working on it
Mr. Monroe does have a lot to do. However, the issue with Fibertower is interesting. Looking at the last post in this thread, the Debtors are using an artificially low valuation partly precipitated by their own, perhaps willing underfunding, of the business during better times. The FCC criticized Fibertower for not funding its business properly, and thereby began proceedings to reclaim the licenses. The FCC may be right. This would not be the first time corporate management willingly took a firm into bankruptcy in order to enrich themselves with new equity in the new enterprise (especially if there were issues with the old business anyway, which there were). The bankruptcy process seeks to preserve the value of the going concern for obvious reasons, hence it is natural that the judge would issue a stay on the FCC. Without the licenses, there is no business other than the existing services (which suffered badly for its own reasons). What is needed is an outside valuation by a third party. Sometimes the note holders and pre-existing corporate management can work together, rather than at cross purposes, to maintain a low value, obtain complete control of the firm, and then move on to a post bankruptcy strategy which could easily have been presented in court but was not, because such presentation might result in a loss of control. What Fibertower needs is either a court appointed examiner to value the business or equity shareholders to sue for a valuation and, based upon that, an equity committee, especially assuming the licenses stay with Fibertower. The FCC can take back their licenses, if they have grounds. Managerial incompetence or malfeasance could be those grounds, but currently they would have to be proven to the judge. Replacing management would have to be done in conjunction with the noteholders who might already be friendly to existing management or potentially new management. I would appreciate comments from others, thanks
I find it insulting to read the debtors response to the unsecured creditors claims. They constantly reference the valuation of the company through Tom Scott's findings. Keep in mind that Tom Scott was the CFO during the time when capital of $12-$18M should have been outlaid to secured their spectrum holdings. Tom Scott, Kurt Van Wagenen, and the Board could not be so stupid as to jeopardize their primary asset unless they knew something. As the unsecured creditors state, why are debtors going to such extremes to preserve an enterprise value of $8.5M that Tom Scott claims. The whole thing stinks to high heaven and I still think that there are many more appeals and possible lawsuits if a judge rules in favor of this sham plan the debtors put forward. Think about who is putting forth the valuation for chapter 11 purposes. Tom Scott and the Debtors. I read the unsecured creditors arguments and it appears well founded with the potential for an enterprise value of $220 Million and possibly much more. I read the debtors response to the unsecured creditors and they are trying to justify $8.5M enterprise value. In a time where wireless and alternative broadband is exploding such as Vivint's method of delivery how do you go from $288M to $106M to $8.5M. It just seems so blatant that I am having a hard time figuring out what the debtors are trying to pull off
Financial analysts are motley FOOLS
I m not sure where many so called financial analysts come from but they wear their title loosely. I do not view many on wall street to be competent or astute when it comes to analyzing and then reporting their findings. On OPK many analysts cited the earnings report as a mixed bag claiming their losses were wider than expected. Well losses in a company that is highly noted as an medical R&D house - spends money on investments in their future vs losses that come from poor execution on a product line. To speak of losses in R&D as you would with companies making a product is beyond foolish - it is well stupid. OPK will easily spend millions testing new products in lengthy and complicated trials or R&D phase but their track record of producing winners is exceptional. What is likely occurring is manipulating a stock rather than honest journalism and scientific investigating. it is sad that this is the best our financial industry has to offer. Perhaps it is only fitting that many in financial institutions today were failures at one point while taking their academic journey. Motley Fools seems to support my claim on tis one
From vix1830
I suspect that Dr Frost has a team of Investment Bankers that are now working in unison with at the very least Soro's team Bonderman/TPA capital. This price action we have seen over the last few days is the execution of the short trap/ short rope the dopes as Mohamed Ali said. Let your opponent think he's landing blows exhaust his capital then deliver the final knock out attack on the shorts. These pathetic lemming quantitative analysts think they can use hyper trading and logarithm trading to beat it down these stocks, but the other side has the same stuff plus they're BILLIONAIRES, not vulnerable leveraged traders. Within 3 months their capital level will be mortally wounded and most will implode. The margin calls started yesterday for the Shorts as the major indexes hit new highs. They now are unwinding the long side hedge which I believe are Rus 2000 ETF and Options hence the drop at 1:00 pm in Bio's and Tech's while the S&P and Dow stayed strong. TSRO, TEVA RXII TRXC all are moving up
Sure would like to know exactly what Dr. Frost is planning....going to be one hellva squeez.
Goog Morning OPK'ers...MM's just shaking to accumulate,buy,sell,short repeat. Buying any dips and watching for voulume to set new support lines.Will be a fight towards end of month between Market Makers who took the call $14 or put $14.
Very few IMO.
Still very positive on RMTI.All Shorties,retail,MM's,ect, really got caught with a Stock with only 40 Million float. I like the targets put out from $16-$19.
I have started tweeting about FTWRq. More than one way to skin a cat.
I have now,thanks for the link.
Play it how ya want but FYI opk has regn written all over it.
Bondholders and for that matter everyone knows that Insiders,CEO,ect let the FTWR fall into Bankruptcy so they could somehow cash out.Well they got screwed and even if bonds win the Common sharholders lawsuit will bring out their secrets.We will see how they manage to please us without dragging out their names in open court & the Media.
Do you have facts? and what convertible note holders have sold their rights? IMO the big short funds,Cidel & Lakewood are borrowing shares from options they have through brokers to sell into runs and continue to short.
Who knows but when gap @ $11.30ish gets filled a measured move from 11 is $15. $7.31-$11.31 = $4
Unlike others Market Makers or forces unknown are keeping PPS very tight.I wouldn't be surprised that almost all shares offered are air shares as who in the f_ _ _k would sell.Most will get a pop to induce players and run some so MM's can make some form of market and make $. IMO with what we know about Big money buying commons there's still alot more than hope.If you don't need tax write off YET data is only increasing in value.
After a year of postponements for launch of 4kscore it is surly welcome to longs and with Phase 3 drugs in pipeline should be a longterm play.
Can't or hard to chart,I have birdies in my ear and your looking at a 40 million Float.....moves fast.
Don't forget RMTI if I forgot to mention it.News soon and expecting a run to $15,possible squezz to $16-19.
Nice charting,I forgot how on Ihub,been close to 2 years...thanks. With possible squeez....OPK is a tiger by the tail.
Had some spam problems with Ihub but have good security now.Been trading the whole time.Retired last year from contracting.RMTI and OPK should have neddle moving news soon.
Longtime....how ya doing? Still been at it everyday,just above $6 and options now.OPK is a winner.
Lets start by saying ain't nothing they can't do,be it naked shorting,rumors,setting a tesla car on fire,ya get the point.Now the hegies thats short[Lakewood & Cidel]will buy options and bank millions of shares that Market Makers will let them borrow against to short.As long as any account is a margin account brokers can lend your or anyones shares out.Hegies are on a first name basis with market makers so they usually go along and them[MM's]MM's will naked short because they make the market..... but with the float shrinking while short intrest rises to all time highs IMO OPK is a TICKING TIME BOMB for shortie.
TICK TOCK
PS 4KScore will be a game changer they can't stop.
Longtime buddy,sent ya a tweet.OPK....don't let this one get away.I'm holding to at least 2016 and looking @ $20-$30 with a possible another regn in the making.Squezz coming soon,not very but soon.
OPK
215M shares in the float. 155M shares owned by Frost. That leaves 60M shares. 46M are short. That leaves 14M shares in the float. At least 5m-10M more shares are held tight by long term investors. That leaves only 4M shares in the float. I don't think a lot of investors here realize what a massive short squeeze we could start any day that will break us thru to new highs. Last week we bumped up against the resistance at $9.15. This week we could break thru it. With the 4K launch in 3 weeks, and other good news coming, I see us hitting new highs to go along with uptrend.